(2S)-2-(2-chlorophenyl)cyclohexan-1-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S)-2-(2-chlorophenyl)cyclohexan-1-one
• 化学式: C₁₂H₁₃ClO
• 分子量: 208.68
• InChiKey: UOEXWLLNMGAJDD-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] PRODRUGS OF KETAMINE, COMPOSITIONS AND USES THEREOF<br/>[FR] PROMÉDICAMENTS À BASE DE KÉTAMINE, COMPOSITIONS ET UTILISATIONS DE CEUX-CI
  申请人：XW LAB INC

  公开号：WO2019137381A1

  公开（公告）日：2019-07-18

  Provided are prodrugs of (S) -or (R) -ketamine, including isotopically labeled ketamine,composition and uses thereof. Compounds having formula (Ia) or (Ib) as the prodrugs of (S) -or (R) -ketamine, including isotopically labeled ketamine, and pharmaceutical compositions comprising the compounds provided herein are used for treating or preventing a CNS disease.More particularly, the related diseases include depression and pain. (Ia) (Ib)

  提供了（S）-或（R）-氯胺酮的前药，包括同位素标记的氯胺酮，其组成和用途。具有化学式（Ia）或（Ib）的化合物作为（S）-或（R）-氯胺酮的前药，包括同位素标记的氯胺酮，以及包含本文提供的化合物的药物组合物用于治疗或预防中枢神经系统疾病。更具体地，相关疾病包括抑郁症和疼痛。（Ia）（Ib）
• [EN] (S)-CSA SALT OF S-KETAMINE, (R)-CSA SALT OF S-KETAMINE AND PROCESSES FOR THE PREPARATION OF S-KETAMINE<br/>[FR] SEL (S)-CSA DE S-KÉTAMINE, SEL (R)-CSA DE S-KÉTAMINE ET PROCÉDÉS PERMETTANT LA PRÉPARATION DE S-KÉTAMINE
  申请人：CHEN CHENG YI

  公开号：WO2016180984A1

  公开（公告）日：2016-11-17

  The present invention is directed to processes for the preparation of esketamine. The present invention is further directed to processes for the resolution of S-ketamine from a racemic or enantiomerically enriched mixture of ketamine. The present invention is further directed to an (S)-CSA salt of S-ketamine, more particularly a monohydrate form of the (S)-CSA salt of S-ketamine; and to an (R)-CSA salt of R-ketamine.

  本发明涉及制备左旋氯胺酮的方法。本发明进一步涉及从消旋或对映体富集混合物中分离S-氯胺酮的方法。本发明还涉及S-氯胺酮的(S)-CSA盐，更具体地是(S)-CSA盐的单水合物形式；以及R-氯胺酮的(R)-CSA盐。
• Process for synthesis and purification of (2R,6R)-hydroxynorketamine
  申请人：THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

  公开号：US11186539B2

  公开（公告）日：2021-11-30

  A process for the preparation of (2R,6R)-hydroxynorketamine is provided. The process requires no chromatography purification and affords the (2R,6R)-hydroxynorketamine in eight steps with a 26% overall yield and greater than 97% purity.

  本发明提供了一种制备 (2R,6R)-羟基炔诺克胺的工艺。该工艺无需色谱纯化，只需八个步骤即可制备出(2R,6R)-羟基软骨胺，总收率为 26%，纯度高于 97%。
• (S)-CSA SALT OF S-KETAMINE, (R)-CSA SALT OF S-KETAMINE AND PROCESSES FOR THE PREPARATION OF S-KETAMINE
  申请人：Janssen Pharmaceutica NV

  公开号：EP3294704B1

  公开（公告）日：2019-10-30
• CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE
  申请人：The United States of America, As Represented by the Secretary, Department of Health and Human Serv

  公开号：US20190135732A1

  公开（公告）日：2019-05-09

  The disclosure provides a method for synthesizing free base forms of (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine. In an embodiment synthesis of (2R,6R)-hydroxynorketamine (HNK) includes preparation of (R)-norketamine via chiral resolution from racemic norketamine via a chiral resolution with L-pyroglutamic acid. The disclosure also provided crystal forms of the corresponding (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine hydrochloride salts.